Novo Holdings Commits USD 100 Million Investment in Asceneuron
Novo Holdings has announced a $100 million investment in Swiss biotech firm Asceneuron, aimed at accelerating the development of innovative treatments for neurodegenerative diseases. This strategic funding highlights the potential impact of Asceneuron’s research on the biotech industry and patient care.